About Me

I’m a PhD student at the Department of Clinical Neuroscience, Karolinska Institutet, Sweden. My research is focused on pharmacoepidemiological studies of disease modifying therapies for multiple sclerosis.



  • Cancer Risk among Swedish Multiple Sclerosis Patients: A Nationwide Cohort Study Comparing Rituximab, Fingolimod, and Natalizumab

    ECTRIMS 2018, Berlin, Germany—Oral presentation

    P. Alping, F. Piehl, and T. Frisell

  • Baseline Characteristics from the COMBAT-MS Study: Initial Analyses Suggest Main Driver for Therapy Choice Is Geographic Location

    ECTRIMS 2017, Paris, France—Poster

    P. Alping, J. Burman, K. Fink, M. Gunnarsson, J. Lycke, P. Nilsson, J. Salzer, M. Vrethem, A. Langer-Gould, A. Svenningsson, T. Frisell, and F. Piehl